<DOC>
	<DOCNO>NCT01910545</DOCNO>
	<brief_summary>The purpose study test safety tolerability investigational drug call OTS167 . OTS167 maternal embryonic leucine zipper kinase ( MELK ) inhibitor demonstrate antitumor property laboratory test . It develop anti-cancer drug . In first-in-human study OTS167 administer patient solid tumor respond treatment .</brief_summary>
	<brief_title>Phase 1 Study OTS167 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1 . Male female patient , &gt; = 18 year age time obtain informed consent . 2 . Patients document ( histologically cytologicallyproven ) solid tumor malignancy locally advance metastatic . 3 . Patients malignancy either refractory standard therapy standard therapy available . 4 . Patients malignancy currently amenable surgical intervention due either medical contraindication nonresectability tumor . 5 . Patients measurable nonmeasurable disease accord response evaluation criterion solid tumor ( RECIST , v1.1 ) 6 . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . 7 . Patients , male female , either childbearing potential agree use medically effective method contraception study 3 month last dose study drug . 8 . Patients ability understand give write informed consent participation trial , include evaluation procedure specify protocol . 1 . Women pregnant lactating . Women childbearing potential ( WOCBP ) , fertile men WOCBPpartner use adequate birth control . 2 . Patients known central nervous system ( CNS ) leptomeningeal metastasis control prior surgery radiotherapy , patient symptoms suggest CNS involvement treatment require . 3 . Patients hematologic malignancy . This include leukemia ( form ) , lymphoma , multiple myeloma . 4 . Patients follow hematologic abnormality baseline : Absolute neutrophil count ( ANC ) &lt; 1,500 per mm3 Platelet count &lt; 100,000 per mm3 5 . Patients follow serum chemistry abnormality baseline : Total bilirubin &gt; = 1.5 × ULN institution Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; = 3 × upper limit normal ( ULN ) institution ( &gt; = 5 × due hepatic involvement tumor ) Serum albumin &lt; 2.5 g/dL Creatinine &gt; = 1.5 × ULN institution ( calculated creatinine clearance &lt; 60 mL/min/1.73 m2 ) 6 . Patients significant cardiovascular disease condition , include : Congestive heart failure ( CHF ) currently require therapy Need antiarrhythmic medical therapy ventricular arrhythmia Severe conduction disturbance Angina pectoris require therapy Corrected QT ( QTc ) interval &gt; 450 msec ( male ) &gt; 470 msec ( female ) QTc interval &lt; = 300 msec History congenital long QT syndrome congenital short QT syndrome Left ventricular ejection fraction &lt; 50 % Uncontrolled hypertension ( per Investigator 's discretion ) Class III IV cardiovascular disease accord New York Heart Association 's ( NYHA ) Functional Criteria . Myocardial infarction ( MI ) within 6 month prior first study drug administration 7 . Patients know suspected hypersensitivity component OTS167 . 8 . Patients known history human immunodeficiency virus ( HIV ) active infection hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . 9 . Patients serious/active/uncontrolled infection , infection require parenteral antibiotic , unexplained fever &gt; 38ºC within 1 week prior first study drug administration . 10 . Patients inadequate recovery acute toxicity associate prior antineoplastic therapy . 11 . Patients inadequate recovery prior surgical procedure , patient undergo major surgical procedure within 4 week prior first study drug administration . 12 . Patients lifethreatening illness , significant organ system dysfunction , clinically significant laboratory abnormality , , opinion Investigator , would either compromise patient 's safety interfere evaluation safety study drug . 13 . Patients psychiatric disorder alter mental status would preclude understand informed consent process and/or completion necessary study . 14 . Patients inability foreseeable incapacity , opinion Investigator , comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>